DarioHealth (DRIO) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRIO shares.
View DRIO analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1-year price targets for DarioHealth's shares. Their DRIO share price forecasts range from $6.00 to $15.00. On average, they expect the company's stock price to reach $11.40 in the next year. This suggests a possible upside of 196.9% from the stock's current price.
View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts.

DarioHealth's stock was trading at $4.28 at the beginning of 2023. Since then, DRIO stock has decreased by 10.3% and is now trading at $3.84.
View the best growth stocks for 2023 here.

DarioHealth saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,040,000 shares, an increase of 9.7% from the April 30th total of 1,860,000 shares. Based on an average trading volume of 161,100 shares, the short-interest ratio is presently 12.7 days.
View DarioHealth's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our DRIO earnings forecast.

DarioHealth Corp. (NASDAQ:DRIO) announced its earnings results on Thursday, March, 9th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.09. The firm earned $6.81 million during the quarter, compared to the consensus estimate of $6.65 million. DarioHealth had a negative trailing twelve-month return on equity of 39.28% and a negative net margin of 125.46%. During the same quarter in the previous year, the business earned ($1.09) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

DarioHealth's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Appian Way Asset Management LP (3.88%), Perceptive Advisors LLC (1.19%), BlackRock Inc. (0.57%), MAI Capital Management (0.56%), Susquehanna International Group LLP (0.23%) and Renaissance Technologies LLC (0.22%). Insiders that own company stock include Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen.
View institutional ownership trends.

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRIO stock can currently be purchased for approximately $3.84.

DarioHealth (NASDAQ:DRIO) has a market capitalization of $101.22 million and generates $27.66 million in revenue each year. The company earns $-62,190,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

The company employs 200 workers across the globe.

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The official website for the company is www.mydario.com. The company can be reached via phone at (833) 914-3796, via email at ir@mydario.com, or via fax at 972-4770-4059.